LG launches upgraded pathology AI model
LG AI Research unveiled its next-generation medicine artificial intelligence (AI) model — the EXAONE Path 2.0 — as part of its push to revolutionize cancer diagnosis and drug development Wednesday. The AI research arm of LG Group launched the EXAONE Path 1.0 in August last year, which the company said represented a “significant advancement” in the use of multimodal AI in oncology. The new EXAONE Path 2.0 has been trained on high-quality data to analyze genetic mutations, expression patterns and subtle structural changes in human cells and tissues through pathology slide images, the AI lab said. This enables earlier cancer diagnosis and more accurate prognosis, thereby helping doctors set personalized treatment plans. It is also expected to be used for more efficient drug development. Leveraging multimodal data — including DNA, RNA and pathology images — the EXAONE Path 2.0 integrates high-resolution whole slide images (WSI), each comprising gigabytes of cellular data with multiomics information. Such images are traditionally broken into thousands of patches for analysis, whichWeiter zum vollständigen Artikel bei Korea Times
Ausgewählte Hebelprodukte auf Ai
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ai
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Korea Times
Nachrichten zu Ai Holdings Corp
Analysen zu Ai Holdings Corp
Keine Analysen gefunden.